Precision oncology company ArcherDx files for $100 million IPO
from Clinical OMICs News
Precision oncology company ArcherDx has disclosed plans to raise $100 million through an initial public offering, according to a registration statement filed with the U.S. Securities and Exchange Commission. ArcherDx has yet to spell out how much in net proceeds it expected to generate — which would depend on how much money the company agrees to raise in the IPO — or how much it would set aside toward the purposes outlined in its S-1 registration statement.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063